UK court OKs Herceptin biosimilar

Share this article:

Biosimilar Herceptin is coming to the UK. Bloomberg reports that a London judge declared two of Roche's patents invalid.

Herceptin patents were set to expire in July but Bloomberg notes this lawsuit was over two additional patents that applied to dosing and composition.

Roche has been preparing for a Herceptin biosimilar for some time, including landing regulatory approval for breast cancer treatment Kadcyla.

Dubbed “super Herceptin,” this treatment combines blockbuster Herceptin with a taxane chemotherapy, as well as a third chemical developed by San Francisco-based ImmunoGen and licensed by Genentech that binds the medicines together.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.